medwireNews: Guselkumab is now available to a wider population of UK patients with psoriatic arthritis (PsA) than it was previously, following an updated recommendation from the National Institute for Health and Care Excellence (NICE).
The interleukin (IL)-23 inhibitor was initially recommended for people with moderate-to-severe PsA in the UK, but may now be given to those with active PsA without restrictions based on psoriasis symptom severity. Guselkumab is recommended for those who have previously been exposed to two conventional DMARDs and one biologic, unless contraindicated.
In a statement to the press, Laura Coates (University of Oxford, UK) said: “Despite increasing numbers of therapies, there still exists a significant unmet need in psoriatic arthritis.
“Improving access to new therapies is crucial to enable clinicians to select the most appropriate therapy for each individual patient, so this is welcomed news for those living with PsA.”
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group